Key result
Aspirin lacks sufficient evidence for universal use as sole primary orthopaedic thromboprophylaxis.
Why the study?
Aspirin has gained renewed attention for VTE prevention after major orthopaedic procedures, but evidence remains heterogeneous and complicated by differences in regimens, timing, and modern fast-track pathways.
Does aspirin prevent symptomatic deep vein thrombosis, pulmonary embolism, major bleeding, and mortality in patients undergoing major orthopaedic procedures compared to LMWH or DOACs?
Comparison
Aspirin vs standard pharmacological options such as LMWH and DOACs
Design
Structured evidence-based review conducted in accordance with PRISMA 2020 principles
Authors
Loading...
Aspirin may offer a practical VTE prophylaxis option post-THA/TKA; extends guideline considerations for cost-effective, low-bleeding alternatives in orthopaedic patients.
Systematic Review
Does aspirin prevent symptomatic deep vein thrombosis, pulmonary embolism, major bleeding, and mortality in patients undergoing major orthopaedic procedures compared to LMWH or DOACs?
Aspirin may be suitable for VTE prophylaxis in orthopaedic surgery within sequential or risk-adapted protocols, but current evidence does not support its universal use as sole primary prophylaxis.
Riediger et al. (2026) conducted a systematic review in Venous thromboembolism in orthopaedic surgery. Aspirin vs. Anticoagulants (LMWH or DOACs) was evaluated on Symptomatic deep vein thrombosis, pulmonary embolism, major bleeding, and mortality. Aspirin may have a role in orthopaedic thromboprophylaxis within structured protocols, but evidence from 9 RCTs does not support its universal use as sole primary prophylaxis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: